Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Aim: Although some relationships between gut microbiota and liver diseases have been reported, it remains uncertain whether changes in gut microbiota owing to differences in race, food and living environment have similar effects. Response to ursodeoxycholic acid (UDCA) may predict the long‐term prognosis of patients with primary biliary cholangitis (PBC); however, little is known about the significance of the gut microbiome in patients with PBC. We elucidated the relationships among clinical profiles, biochemical response to UDCA and gut microbiome composition in patients with PBC. Methods: Fecal samples from 76 patients with PBC treated at our hospital were collected; patients whose UDCA intake period was <1 year were excluded. The microbiome structures of patients were determined using 16S ribosomal RNA gene sequencing and were statistically compared with those of healthy subjects. The structures of patients in the UDCA responder (n = 43) and non‐responder (n = 30) groups were compared according to the Nara criteria (reduction rate of gamma‐glutamyl transpeptidase, ≥69%, after 1 year). Results: Compared with healthy subjects, bacterial diversity was lower in patients with PBC, with a decreased abundance of the order Clostridiales and increased abundance of Lactobacillales. The UDCA non‐responder group had a significantly lower population of the genus Faecalibacterium, known as butyrate‐producing beneficial bacteria (P < 0.05), although no significant differences in gender, body mass index, medicated drugs or other serological data were indicated between these two groups. Conclusions: Gut dysbiosis with loss of beneficial Clostridiales commensals was observed in patients with PBC. Decrease in Faecalibacterium abundance might predict the long‐term prognosis of patients with PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
The bile acid receptor FXR is a modulator of intestinal innate immunity
Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803978 · Cited by 655
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Tang, R., Wei, Y., Li, Y., Chen, W., Chen, H., Wang, Q., Yang, F., Miao, Q., Xiao, X., Zhang, H., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313332 · Cited by 434
Cipriani, S., Mencarelli, A., Chini, M. G., Distrutti, E., Renga, B., Bifulco, G., Baldelli, F., Donini, A., & Fiorucci, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025637 · Cited by 382
Martín, R., Miquel, S., Chain, F., Natividad, J. M., Jury, J., Lu, J., Sokol, H., Theodorou, V., Bercik, P., Verdu, E. F., et al. (2015) · BMC Microbiology · doi:10.1186/s12866-015-0400-1 · Cited by 309
Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease
Fujimoto, T., Imaeda, H., Takahashi, K., Kasumi, E., Bamba, S., Fujiyama, Y., & Andoh, A. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12073 · Cited by 304
Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis
Corpechot, C., Chrétien, Y., Chazouillères, O., & Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.019 · Cited by 235
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234
Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis
Carlsson, A. H., Yakymenko, O., Olivier, I., Håkansson, F., Postma, E., Keita, Å. V., & Söderholm, J. D. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.828773 · Cited by 219
Gut dysbiosis associated with hepatitis C virus infection
Inoue, T., Nakayama, J., Moriya, K., Kawaratani, H., Momoda, R., Ito, K., Iio, E., Nojiri, S., Fujiwara, K., Yoneda, M., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy205 · Cited by 183
Self-citationA comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors
Clooney, A. G., Bernstein, C. N., Leslie, W. D., Vagianos, K., Sargent, M., Laserna‐Mendieta, E. J., Claesson, M. J., & Targownik, L. E. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13568 · Cited by 166
Lopez-Siles, M., Martinez-Medina, M., Surís-Valls, R., Aldeguer, X., Sabat-Mir, M., Duncan, S. H., Flint, H. J., & Garcia-Gil, L. J. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000590 · Cited by 144
Bosch, A., Dumortier, J., Maucort-Boulch, D., Scoazec, J.-Y., Wendum, D., Conti, F., Morard, I., Rubbia-Brandt, L., Terris, B., Radenne, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.038 · Cited by 114
Environmental factors in primary biliary cirrhosis
Juran, B., & Lazaridis, K. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1383726 · Cited by 89
Cited by
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases
Cargill, T., & Culver, E. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661196 · Cited by 46
Gut microbial profile of treatment-naive patients with primary biliary cholangitis
Zhou, Y.-J., Ying, G.-X., Dong, S.-L., Xiang, B., & Jin, Q.-F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126117 · Cited by 26
“(12) studied PBC patients from Japan and reported they had significantly reduced diversity of gut microbiota, with abnormal increases of Enterococcus, Streptococcus, Lactobacillus, and Bifidobacterium, and a significant decrease of Clostridiales.”
Background
Metadata
- Authors
- Furukawa, M., Moriya, K., Nakayama, J., Inoue, T., Momoda, R., Kawaratani, H., Namisaki, T., Sato, S., Douhara, A., Kaji, K., Kitade, M., Shimozato, N., Sawada, Y., Saikawa, S., Takaya, H., Kitagawa, K., Akahane, T., Mitoro, A., Yamao, J., Tanaka, Y., & Yoshiji, H.
- Venue
- Hepatology Research
- Publisher
- Wiley
- Published
- 2020-06-10
- Volume
- 50
- Issue
- 7
- Pages
- 840-852
- ISSN
- 1386-6346 (ISSN-L)
- 1872-034X
- OpenAlex
- W3018781948
- Cited by
- 85
- References
- 21
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.